(+)-1-methyl-trans-2-phenylcyclopropanecarboxylic acid | 13005-22-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (+)-1-methyl-trans-2-phenylcyclopropanecarboxylic acid
• 英文别名: 1-Methyl-2-phenylcyclopropane-1-carboxylic acid；(1R,2S)-1-methyl-2-phenylcyclopropane-1-carboxylic acid
• CAS: 13005-22-6
• 化学式: C₁₁H₁₂O₂
• mdl: MFCD28100909
• 分子量: 176.215
• InChiKey: UXLNWWCUHTZUTE-GXSJLCMTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (+)-1-methyl-trans-2-phenylcyclopropanecarboxylic acid 在 臭氧 、 溶剂黄146 作用下， 生成 反式-1-甲基-1,2-环丙烷二羧酸
  参考文献：
  名称：

  Perold, Journal of the South African Chemical Institute, 1955, vol. 8, p. 1,9

  摘要：

  DOI：
• 作为产物：
  描述：

  3-甲基-5-苯基-四氢呋喃-2-酮 在 potassium tert-butylate 作用下， 生成 (+)-1-methyl-trans-2-phenylcyclopropanecarboxylic acid
  参考文献：
  名称：

  Chemistry of Cyclopropanols. V. Stereochemistry of Acid- and Base-Catalyzed Ring Opening^1,2

  摘要：

  DOI：

  10.1021/ja00966a030

文献信息

• TETRAZOLE-CONTAINING 1,2-CYCLOPROPANE-CARBOXAMIDES
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20190194148A1

  公开（公告）日：2019-06-27

  The present invention relates to N-(tetrazolylaryl) amide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式(I)所描述和定义的N-(四唑基芳基)酰胺化合物，涉及包含该化合物的药物组合物和配方，以及利用该化合物制造用于治疗或预防疾病的药物组合物，特别是神经源性障碍，作为唯一药剂或与其他活性成分结合使用。
• COMPLEMENT PATHWAY MODULATORS AND USES THEREOF
  申请人：Altmann Eva

  公开号：US20150141455A1

  公开（公告）日：2015-05-21

  The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了化合物I的公式：（I），本发明的化合物制备方法及其治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。
• Kaiser,C. et al., Journal of medicinal and pharmaceutical chemistry, 1962, vol. 5, p. 1243 - 1265
  作者：Kaiser,C. et al.

  DOI：——

  日期：——
• [EN] COMPLEMENT PATHWAY MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE LA VOIE DU COMPLÉMENT ET LEURS UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2014002051A3

  公开（公告）日：2014-03-20
• Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: A novel class of irreversible inhibitors of histone demethylase KDM1A
  作者：Paola Vianello、Oronza A. Botrugno、Anna Cappa、Giuseppe Ciossani、Paola Dessanti、Antonello Mai、Andrea Mattevi、Giuseppe Meroni、Saverio Minucci、Florian Thaler、Marcello Tortorici、Paolo Trifiró、Sergio Valente、Manuela Villa、Mario Varasi、Ciro Mercurio

  DOI：10.1016/j.ejmech.2014.08.068

  日期：2014.10

  Histone demethylase KDM1A (also known as LSD1) has become an attractive therapeutic target for the treatment of cancer as well as other disorders such as viral infections. We report on the synthesis of compounds derived from the expansion of tranylcypromine as a chemical scaffold for the design of novel demethylase inhibitors. These compounds, which are substituted on the cyclopropyl core moiety, were evaluated for their ability to inhibit KDM1A in vitro as well as to function in cells by modulating the expression of Gfi-1b, a well recognized KDM1A target gene. The molecules were all found to covalently inhibit KDM1A and to become increasingly selective against human monoamine oxidases MAO A and MAO B through the introduction of bulkier substituents on the cyclopropylamine ring. Structural and biochemical analysis of selected trans isomers showed that the two stereoisomers are endowed with similar inhibitory activities against KDM1A, but form different covalent adducts with the FAD co-enzyme. (C) 2014 Elsevier Masson SAS. All rights reserved.